Carlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
If you are not happy with the results below please do another search
50 search results for:
New Mexico agreed to join a proposed nationwide settlement worth up to $21 billion resolving claims that the three largest U.S. drug distributors fueled a deadly opioid epidemic, the state’s attorney general said on December 7.
The World Health Organization updated its guidelines for COVID-19 treatments against the use of convalescent plasma for all cases of infection.
The U.S. Federal Trade Commission and seven states on December 7 settled claims accusing Vyera Pharmaceuticals of trying to block generic versions of the company’s life-saving drug Daraprim, but are preparing for a Dec. 14 trial against accused mastermind Martin Shkreli.
The shares of Utah-based Recursion climbed on December 7 after the company announced entering into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions of dollars to identify and develop up to 40 new medications for neuroscience and oncology.
EU health agencies recommended that Covid-19 vaccines be mixed and matched for both initial courses and booster doses as the region battles rising cases ahead of Christmas.
Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from the company’s pipeline and discovery platform.
Shares of vTv Therapeutics climbed in trading on December 7 after the company announced plans to restructure and reduce head count by 65 percent in order to ensure funding for a Phase III trial for lead diabetes program TTP399.
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
GSK said on December 7 the British drugmaker’s antibody-based Covid-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.